Wednesday 14/January/2026 – 11:28 AM
The U.S. Food and Drug Administration (FDA) has asked drug companies to remove warnings about the potential for self-destructive thoughts or behaviors from weight-loss drug labels. the weight Commonly known as GLP-1 drugs, a regulatory review found no evidence linking these drugs to increased psychiatric risks, according to Reuters.
The US Food and Drug Administration calls for the removal of self-disposal warnings on weight-loss drug labels
The decision includes Novo Nordisk’s Wijovi drugs, Eli Lilly’s Zipbound, as well as the older weight loss drug Saxenda.
The authority explained that the previous warnings were included when first approving these drugs, based on general reports observed with other old weight loss drugs, and not based on direct evidence regarding GLP-1 drugs.
The FDA said its comprehensive review did not show a link between GLP-1 receptor agonists and an increased risk of distressed thoughts or behaviors, nor was there an increase in other psychiatric side effects such as anxiety, depression, irritability or psychosis.
The authority added that it analyzed the data of 91 placebo-controlled clinical trials, which included about 107,000 patients, more than 60,000 of whom received GLP-1 medications, without detecting significant differences compared to the other group.
This decision may help allay concerns about the safety of this fast-growing drug class, which is not only used for weight loss, but is also being tested or used to treat cardiovascular disease, fatty liver disease, and sleep apnea.
For their part, Novo Nordisk and Eli Lilly welcomed the Food and Drug Administration’s recommendation, and confirmed their cooperation with the authority to update drug labels and provide appropriate safety information to doctors.
It is noteworthy that the labels of these medicines in the European Union do not include similar warnings.
